Valente Manuela 4/A

4/A · SOPHiA GENETICS SA · Filed Apr 8, 2026

AI-generated summary of this filing

Updated Apr 8, 2026

SOPHiA GENETICS (SOPH) CPO Manuela Valente Receives RSU/Option Award

What Happened

Manuela Valente, Chief People Officer of SOPHiA GENETICS (SOPH), was granted equity awards on April 2, 2026: 71,869 restricted stock units (RSUs) and 104,790 derivative awards (total 176,659). Both were reported as acquired at $0.00 (typical for compensation grants). Following an amended Form 4, the correct total of ordinary shares she beneficially owns is 224,248 (the original filing misstated this number).

Key Details

Transaction date: April 2, 2026; Form 4 filed April 8, 2026 as an amendment to the April 3, 2026 filing to correct the ownership amount (see F2).
Grant amounts and price: 71,869 RSUs @ $0.00; 104,790 derivative awards @ $0.00 (total 176,659 awards).
Shares beneficially owned after transaction: 224,248 ordinary shares (corrected amount per F2).
Vesting: RSUs vest 25% on April 2, 2027, then the remaining 75% in equal quarterly installments through April 2, 2030 (F1). The derivative award vests 25% on April 2, 2027, then in equal monthly installments through April 2, 2030 (F3).
Filing note: This is a Form 4/A amending the April 3 filing to correct the amount of shares reported as beneficially owned.

Context

These are compensation awards (RSUs and a derivative/option-style grant) that vest over multi-year schedules and are contingent on continued service — they do not represent open-market purchases or immediate sales. Until vesting (and, for options, exercise), they have limited liquidity and do not necessarily indicate a near-term trading intent.

Form 4/AAmended

Period: 2026-04-02

Chief People Officer

Transactions

Award
Ordinary Shares
[F1][F2]
2026-04-02+71,869→ 224,248 total
Award
Share Option (Right to Buy)
[F3]
2026-04-02+104,790→ 104,790 total
Exercise: $5.04Exp: 2036-04-02→ Ordinary Shares (104,790 underlying)

Footnotes (3)

[F1]Represents a restricted stock unit ("RSU") grant made under the Issuer's 2021 Equity Incentive Plan. Each RSU represents a contingent right to receive one ordinary share of the Issuer, subject to the Reporting Person's continued service with the Issuer. 25% of the RSUs will vest on April 2, 2027, and the remaining 75% will vest in equal quarterly installments through April 2, 2030.
[F2]This Form 4/A amends the Form 4 filed on April 3, 2026 to correct the amount reported in Column 5 (Amount of Securities Beneficially Owned Following Reported Transaction), which was previously reported as 71,869 ordinary shares due to an inadvertent error. The correct amount is 224,248 ordinary shares.
[F3]The share option vests and becomes exercisable as to 25% of the ordinary shares on April 2, 2027, and then in equal monthly installments through April 2, 2030.

Signature

/s/ Elimara Brunetto as Attorney-in-fact for Manuela Valente|2026-04-08

1 file